Replimune Group (NASDAQ:REPL) Stock Price Down 3.5% - What's Next?

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) fell 3.5% on Friday . The company traded as low as $13.14 and last traded at $13.27. 92,520 shares were traded during trading, a decline of 89% from the average session volume of 869,392 shares. The stock had previously closed at $13.75.

Wall Street Analyst Weigh In

A number of analysts have weighed in on REPL shares. BMO Capital Markets increased their price target on Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a report on Wednesday. HC Wainwright raised their target price on Replimune Group from $17.00 to $21.00 and gave the stock a "buy" rating in a research note on Wednesday. Finally, Jefferies Financial Group boosted their price target on Replimune Group from $16.00 to $19.00 and gave the company a "buy" rating in a research note on Wednesday, December 4th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $19.14.

Replimune Group Trading Down 1.2 %

The firm has a market cap of $929.79 million, a price-to-earnings ratio of -4.46 and a beta of 1.28. The firm's 50-day moving average is $12.28 and its 200-day moving average is $11.35. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.75) by $0.07. As a group, sell-side analysts anticipate that Replimune Group, Inc. will post -2.88 EPS for the current fiscal year.

Insider Transactions at Replimune Group

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the business's stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the transaction, the chief executive officer now directly owns 202,014 shares in the company, valued at $2,509,013.88. The trade was a 4.72 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Konstantinos Xynos sold 7,246 shares of the company's stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the transaction, the insider now owns 109,885 shares in the company, valued at approximately $1,184,560.30. The trade was a 6.19 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 8.80% of the company's stock.

Institutional Trading of Replimune Group

Hedge funds and other institutional investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. boosted its stake in Replimune Group by 12.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company's stock worth $5,313,000 after purchasing an additional 52,498 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Replimune Group by 17.9% in the third quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company's stock worth $15,657,000 after buying an additional 217,308 shares in the last quarter. Barclays PLC lifted its holdings in shares of Replimune Group by 165.5% in the third quarter. Barclays PLC now owns 158,491 shares of the company's stock worth $1,738,000 after buying an additional 98,791 shares in the last quarter. LMR Partners LLP boosted its position in shares of Replimune Group by 145.8% in the third quarter. LMR Partners LLP now owns 82,479 shares of the company's stock valued at $904,000 after acquiring an additional 48,920 shares during the period. Finally, Millennium Management LLC grew its stake in Replimune Group by 575.1% during the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company's stock valued at $28,062,000 after acquiring an additional 2,656,173 shares in the last quarter. Institutional investors own 92.53% of the company's stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.